Key result
AICD linked to ~52% lower one-year mortality compared to expected risk.
Why the study?
The automatic implantable cardioverter-defibrillator was developed to continuously monitor and treat malignant ventricular tachyarrhythmias to improve survival in high-risk patients.
Does the automatic implantable cardioverter-defibrillator reduce mortality in high-risk patients with potentially lethal ventricular tachyarrhythmias?
Observational (n=160)
Does the automatic implantable cardioverter-defibrillator reduce mortality in high-risk patients with potentially lethal ventricular tachyarrhythmias?
Effect estimate: 52% decrease
Absolute Event Rate: 22.9% vs 48%
The automatic implantable cardioverter-defibrillator reliably identifies and corrects potentially lethal ventricular tachyarrhythmias, leading to a substantial increase in survival in properly selected high-risk patients.
No takes yet. Share an insight, caveat, or question.
Supports ICD survival benefit in high-risk ventricular arrhythmia patients; leaves open confirmation by randomized trials.
Mirowski et al. (1984) conducted an observational in Malignant ventricular tachyarrhythmias (n=160). Automatic implantable cardioverter-defibrillator vs. Expected mortality without the device was evaluated on One-year total mortality (52% decrease). The automatic implantable cardioverter-defibrillator resulted in a 22.9% one-year total mortality, a 52% decrease from the 48% expected mortality without the device.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: